The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study

Haagsman, Annika N; Witkamp, Astrid C S; Sjollema, B.; Kik, Marja; Kirpensteijn, Jolle

doi:10.1186/1746-6148-9-155

Cited by 11 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interleukin‐2 (IL‐2) is a pleiotropic cytokine released early during an immune response (Haagsman et al . ). A property that has made IL‐2 attractive as the basis for cancer immunotherapy, is enhancement of the tumoricidal capacity of lymphoid cells, specifically T lymphocytes and natural killer cells (Helfand et al .…”

Section: Introductionmentioning

confidence: 97%

A phase I clinical study to evaluate safety of orally administered, genetically engineeredSalmonella entericaserovarTyphimuriumfor canine osteosarcoma

Fritz

Henson

Greengard

et al. 2016

Veterinary Medicine & Sci

View full text Add to dashboard Cite

We conducted a prospective phase I study to evaluate safety of an orally administered Salmonella encoding IL‐2 (SalpIL2) in combination with amputation and adjuvant doxorubicin for canine appendicular osteosarcoma. Efficacy was assessed as a secondary measure. The first dose of SalpIL2 was administered to 19 dogs on Day 0; amputation was done after 10 days with chemotherapy following 2 weeks later. SalpIL2 was administered concurrent with chemotherapy, for a total of five doses of doxorubicin and six doses of SalpIL2. There were six reportable events prior to chemotherapy, but none appeared due to SalpIL2. Dogs receiving SalpIL2 had significantly longer disease‐free interval (DFI) than a comparison group of dogs treated with doxorubicin alone. Dogs treated using lower doses of SalpIL2 also had longer DFI than dogs treated using the highest SalpIL2 dose. The data indicate that SalpIL2 is safe and well tolerated, which supports additional testing to establish the potential for SalpIL2 as a novel form of adjuvant therapy for dogs with osteosarcoma.

show abstract

Section: Introductionmentioning

confidence: 97%

A phase I clinical study to evaluate safety of orally administered, genetically engineeredSalmonella entericaserovarTyphimuriumfor canine osteosarcoma

Fritz

Henson

Greengard

et al. 2016

Veterinary Medicine & Sci

View full text Add to dashboard Cite

show abstract

“…55 Immunotherapy with interleukin-2 following marginal surgical resection did not prolong survival times in dogs. 52 The major initial differential diagnoses in the case reported here were a leiomyosarcoma or gastrointestinal stromal cell tumour (GIST), which are uncommon to rare in cats, respectively. 56,57 The immunohistochemistry was consistent with a PNST, which are usually S-100 protein and vimentin positive, muscle-specific actin negative and most are glial fibrially acidic protein positive.…”

Section: Discussionmentioning

confidence: 97%

“…22,29–50 Incomplete surgical resection leads to recurrence and metastatic disease is rarely reported. 22,24,39,43,44,46,47,49–52 Stereotactic radiation therapy for canine trigeminal and brachial plexus MPNSTs may prolong survival times when surgical resection is not possible. 28,53 Metronomic cyclophosphamide and piroxicam treatment delays recurrence in dogs with incompletely resected MPNST.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Colonic malignant peripheral nerve sheath tumour in a cat

Boland

Setyo

Sangster

et al. 2019

Journal of Feline Medicine and Surgery Open Reports

View full text Add to dashboard Cite

Case summary A 14-year-old male neutered domestic mediumhair cat presented with a 4 month history of inappetence and weight loss. Pertinent abnormalities on haematology and biochemistry included a mild microcytic regenerative anaemia (packed cell volume [PCV] 24% [reference interval (RI) 30–45%], mean cell volume 30.8 fl [RI 40–45 fl], absolute reticulocyte count 326.8 × 10 12 ) and increased alkaline phosphatase activity (76 IU/l; RI <50 IU/l). Abdominal ultrasound and CT scan revealed masses in the transverse colon (2.0 cm × 1.2 cm) and right medial liver lobe (5.0 cm diameter). Thoracic radiographs were unremarkable. Right medial liver lobe resection and colectomy were performed. Immunohistochemistry was positive for S-100 protein, vimentin and glial fibrillary acidic protein, very weakly positive for c-kit and negative for muscle-specific actin and CD18, consistent with a colonic malignant peripheral nerve sheath tumour (MPNST) with a hepatic metastasis. Postoperative treatment with metronomic cyclophosphamide was well tolerated. Eighteen months postoperatively the cat re-presented after 3 days of progressive lethargy and inappetence. Haematology revealed a marked non- or pre-regenerative anaemia (PCV 10%). Coagulation times were prolonged (prothrombin time 39 s [RI 15–22 s] and activated partial thromboplastin time >300 s [RI 65–119 s]). Abdominal ultrasound identified multiple renal and hepatic nodules. Euthanasia was performed and post-mortem examination confirmed metastasis of the MPNST. Relevance and novel information This report describes the treatment of a metastatic colonic peripheral nerve sheath tumour in a cat. Feline visceral MPNSTs are rare and little is known about prognosis or optimal treatment.

show abstract

“…Interleukin‐2 has been used to treat cancer in several species including humans, dogs, and cats 15‐19 . It also has been used to treat sarcoid tumors in horses 13,14 .…”

Section: Introductionmentioning

confidence: 99%

ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study

Saba

Eggleston

Parks

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Sarcoid tumors are common in horses and may negatively impact the performance and value of the horse. No known treatment is reliably successful.Hypotheses/Objectives: To determine tolerability, overall response rate, time to response, and progression-free survival of horses with biopsy-confirmed or suspected sarcoids treated with ALVAC-fIL2.Animals: Client-owned horses with measurable, presumed-or biopsy-confirmed sarcoid tumors.Methods: Prospective pilot study. One milliliter of ALVAC-fIL2 was injected into 4 to 5 areas of the sarcoid(s) in each horse (week 0); this treatment was repeated in weeks 1, 3, and 7. Sarcoids were measured at each visit, and response to treatment was determined according to the Response Evaluation Criteria in Solid Tumors for dogs (v1.0). After the final treatment, horses were reassessed and sarcoids remeasured every 3 months until tumor progression or for a minimum of 1 year if progression was not documented.Results: Fourteen horses were included. Tumor size decreased in 86% of the horses, and the median time to first response was 89 days (range, 34-406 days). Median time to best response was 211 days (range, 56-406 days), but 3 of the sarcoids still were decreasing in size at the time of final evaluation. The median progression-free interval was not reached. Adverse events were minimal and included transient focal inflammation in 2 horses.Conclusions and Clinical Importance: Intratumoral injection of ALVAC-fIL2 has promise as a well-tolerated and effective, tissue-sparing treatment for horses with sarcoid tumors.

show abstract

The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study

Cited by 11 publications

References 39 publications

A phase I clinical study to evaluate safety of orally administered, genetically engineeredSalmonella entericaserovarTyphimuriumfor canine osteosarcoma

A phase I clinical study to evaluate safety of orally administered, genetically engineeredSalmonella entericaserovarTyphimuriumfor canine osteosarcoma

Colonic malignant peripheral nerve sheath tumour in a cat

ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study

Contact Info

Product

Resources

About